Information Provided By: 
Fly News Breaks for August 8, 2019
AERI
Aug 8, 2019 | 07:42 EDT
Oppenheimer analyst Esther Rajavelu lowered her price target for Aerie Pharmaceuticals to $45 from $65, assuming lower near-term revenues, partially offset by a lower WACC. The analyst notes that the company reported Q2 revenues that were slightly above her estimate, but lowered full-year guidance, citing slower uptake of its approved products, Rocklatan and Rhopressa, as the company works to obtain broader access, especially for Rocklatan. Rajavelu reiterates an Outperform rating on the shares.
News For AERI From the Last 2 Days
There are no results for your query AERI
